Aroa Biosurgery Limited

ASX:ARX Voorraadrapport

Marktkapitalisatie: AU$206.9m

Aroa Biosurgery Toekomstige groei

Future criteriumcontroles 5/6

Aroa Biosurgery is forecast to grow earnings and revenue by 56.3% and 20.1% per annum respectively. EPS is expected to grow by 100.9% per annum. Return on equity is forecast to be 14.5% in 3 years.

Belangrijke informatie

56.3%

Groei van de winst

100.9%

Groei van de winst per aandeel

Biotechs winstgroei15.2%
Inkomstengroei20.1%
Toekomstig rendement op eigen vermogen14.5%
Dekking van analisten

Low

Laatst bijgewerkt22 Oct 2024

Recente toekomstige groei-updates

Recent updates

Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Winst- en omzetgroeiprognoses

ASX:ARX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (NZD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/20271332024184
3/31/20261087885
3/31/2025850145
3/31/202469-11-14-7N/A
12/31/202367-9-15-7N/A
9/30/202366-8-15-6N/A
6/30/202365-4-13-5N/A
3/31/2023630-11-4N/A
12/31/202257-1-13-7N/A
9/30/202251-2-15-10N/A
6/30/202245-5-16-11N/A
3/31/202240-8-16-12N/A
12/31/202135-10-14-10N/A
9/30/202131-11-11-8N/A
6/30/202127-15-9-6N/A
3/31/202122-19-7-5N/A
12/31/202022-19-6-5N/A
9/30/202021-19-6-4N/A
6/30/202023-12-3-1N/A
3/31/202025-602N/A
3/31/2019241-20N/A
3/31/201811-1-5-3N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: ARX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Winst versus markt: ARX is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hoge groeiwinsten: ARX is expected to become profitable in the next 3 years.

Omzet versus markt: ARX's revenue (20.1% per year) is forecast to grow faster than the Australian market (5.7% per year).

Hoge groei-inkomsten: ARX's revenue (20.1% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: ARX's Return on Equity is forecast to be low in 3 years time (14.5%).


Ontdek groeibedrijven